Nearly half of participants in a weight loss program who initiated an antiobesity medication and who consumed alcohol at ...

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

The prevention of diabetic retinopathy should involve adequate control of sugar levels, blood pressure, and promoting a ...

The researchers utilized pooled data from the National Health and Nutrition Examination Survey to assess the overlap between the FDA eligibility standards and the exclusion criteria observed in ...

The Biden administration is proposing Medicare and Medicaid coverage for GLP-1 RA obesity medications like semaglutide (Wegovy) and tirzepatide (Zepbound), challenging a two-decade-old law and facing ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

GLP-1s have been heralded for their ability to suppress appetite but did you know that GLP-1 is a natural hormone you can stimulate without injections.

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the ...